RTP Mobile Logo
Select Publications

Banerjee S et al. Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. ESMO 2020;Abstract 811MO.

Chung HC et al. Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase II KEYNOTE-158 study. SGO 2021;Abstract 10440.

Coleman RL et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study. ESMO 2020;Abstract LBA32.

Hong DS et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res 2020;26(6):1220-8. Abstract

How JA et al. The use of pembrolizumab and lenvatinib combination therapy in endometrial cancer: An examination of toxicity and treatment efficacy in clinical practice. SGO 2021;Abstract 10775.

Litton JK et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018;379(8):753-63. Abstract

Madariaga A et al. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer 2020;30(7):903-15. Abstract

Makker V et al. A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician’s choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775. SGO 2021;Abstract 11512.

Makker V et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020;38(26):2981-92. Abstract

Mirza MR et al. ENGOT-EN6/NSGO-RUBY: A phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC). ASCO 2020;Abstract TPS6107.

Oaknin A et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: A nonrandomized phase 1 clinical trial. JAMA Oncol 2020;6(11):1766-72. Abstract

O’Malley D et al. Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study. ESMO 2019;Abstract 1044P.

Pothuri B et al. Interim analysis of the immune-related endpoints of the mismatch repair deficient (dMMR) and proficient (MMRp) endometrial cancer cohorts from the GARNET study. SGO 2021;Abstract 10417.